Cargando…
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, a...
Autores principales: | Tedeschi, Alessandra, Frustaci, Anna Maria, Mauro, Francesca Romana, Chiarenza, Annalisa, Coscia, Marta, Ciolli, Stefania, Reda, Gianluigi, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Baratè, Claudia, Sportoletti, Paolo, Greco, Antonino, Borella, Chiara, Rossi, Valentina, Deodato, Marina, Biagi, Annalisa, Zamprogna, Giulia, Pelle, Angelo Curto, Lapietra, Gianfranco, Vitale, Candida, Morelli, Francesca, Cassin, Ramona, Fresa, Alberto, Cavalloni, Chiara, Postorino, Massimiliano, Ielo, Claudia, Cairoli, Roberto, Di Raimondo, Francesco, Montillo, Marco, Del Poeta, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714729/ https://www.ncbi.nlm.nih.gov/pubmed/34525181 http://dx.doi.org/10.1182/bloodadvances.2021004824 |
Ejemplares similares
-
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022) -
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023) -
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
por: Mauro, Francesca Romana, et al.
Publicado: (2021) -
Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy Hematology Network (REL)
por: Reda, Gianluigi, et al.
Publicado: (2020) -
S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
por: Frustaci, Anna Maria, et al.
Publicado: (2023)